文献速递前列腺癌

疑似前列腺癌后谁从多参数磁共振成像中获益?

Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?
PubMed 文献 · Eur Urol Oncol · 2018-12-14

该回顾性分析纳入2016至2017年一家转诊机构连续768例疑似前列腺癌并计划穿刺的男性,按初诊穿刺与重复穿刺及PSA-直肠指检分组评估多参数磁共振(mpMRI)避免穿刺和漏诊高级别前列腺癌(HGPC)的比例。结果显示PSA≥10ng/ml且直肠指检阳性者无获益,其余男性在初诊和重复穿刺中均可获益。

要点

  • mpMRI对PSA≥10ng/ml且直肠指检阳性的男性无获益。
  • 其余男性中,mpMRI可避免穿刺率最高达25.7%,净增HGPC检出率最高达28.4%。
  • PI-RADS<3可避免穿刺率总体24.2%,初诊25.7% vs 重复20.5%(p=0.057)。

核心结论

  • mpMRI对PSA≥10ng/ml且直肠指检阳性的男性无获益。
  • 其余男性中,mpMRI在初诊和重复穿刺中均有获益,可减少穿刺率最高达25.7%,净增HGPC检出率最高达28.4%。

研究设计与样本

  • 回顾性分析纳入2016年和2017年一家转诊机构连续768例疑似前列腺癌并计划前列腺穿刺的男性。
  • 干预为盆腔3-T mpMRI、对可疑病灶(PI-RADS评分>1)行靶向穿刺及12针系统穿刺。

主要发现

  • 可避免穿刺(PI-RADS<3)率总体24.2%,初诊25.7% vs 重复20.5%(p=0.057)。
  • 初诊和重复穿刺的可避免穿刺率在G1分别为31.2%和19.8%,G2为13.5%和30.4%,G3为23.7%和21.9%,G4为2.5%和0%。
  • 漏诊HGPC总体率初诊1.0% vs 重复6.5%(p=0.170);初诊和重复在G1为1.1%和5.2%,G2为2.0%和11.1%,G3为0%和7.7%,G4为0%和0%(p<0.001)。
  • 靶向穿刺后HGPC(PI-RADS 3-5)诊断率总体初诊增至23.9%、重复增至32.6%(p<0.001);初诊和重复在G1为29.0%和45.5%,G2为20.0%和33.3%,G3为40.0%和38.9%,G4为0%和0%(p<0.001)。

关键数值与推荐

  • 可避免穿刺定义为PI-RADS<3,总体率24.2%。
  • PSA-DRE分组:G1为PSA<10ng/ml且直肠指检阴性;G2为PSA<10ng/ml且直肠指检阳性;G3为PSA≥10ng/ml且直肠指检阴性;G4为PSA≥10ng/ml且直肠指检阳性。

临床怎么用

  • 作者结论认为,除PSA≥10ng/ml且直肠指检阳性的男性外,其余疑似前列腺癌男性均可从mpMRI及靶向穿刺中获益。
  • 作者认为获益包括避免不必要的前列腺穿刺操作和增加侵袭性癌的检出。

局限性

  • 单机构设计。
  • 缺乏随机化。
  • 亚组分析样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer (PC) suspicion is based on prostate-specific antigen (PSA) and digital rectal examination (DRE). Multiparametric magnetic resonance imaging (mpMRI) increases prostate biopsy (PBx) specificity and sensitivity for detection of aggressive PC. OBJECTIVE: To identify who benefits from mpMRI according to biopsy scenario (initial biopsy [IBx] vs repeated biopsy [RBx]) and the risk of aggressive PC according to PSA-DRE groups (G1, PSA <10ng/ml and -DRE; G2, PSA <10ng/ml and +DRE; G3, PSA ≥10ng/ml and -DRE; G4, PSA ≥10ng/ml and +DRE). DESIGN, SETTING, AND PARTICIPANTS: We carried out a retrospective analysis for 768 consecutive men with PC suspicion and scheduled for PBx in a referral institution in 2016 and 2017. INTERVENTION: Pelvic 3-T mpMRI scanning, targeted biopsy (TBx) for suspicious lesions (Prostate Imaging-Reporting and Data System [PI-RADS] score >1), and 12-core systematic biopsy (SBx). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We measured the rate of PBx procedures that could be avoided and the rate of high-grade PC (HGPC) that would be missed among men with negative mpMRI, and the increase in HGPC detection due to TBx. Univariate and multivariate analyses were performed. RESULTS AND LIMITATIONS: The rate of avoidable biopsies (PI-RADS <3) was 24.2% overall, with 25.7% for IBx and 20.5% for RBx (p=0.057). The IBx and RBx rates were 31.2% and 19.8% in G1, 13.5% and 30.4% in G2, 23.7% and 21.9% in G3, and 2.5% and 0% in G4, respectively. The overall rate of missed HGPC was 1.0% for IBx and 6.5% for RBx (p=0.170), while the IBx and RBx rates were 1.1% and 5.2% for G1, 2.0% and 11.1% for G2, 0% and 7.7% for G3, and 0% and 0% for G4, respectively (p<0.001). The rate of HGPC (PI-RADS 3-5) diagnosed following TBx increased to 23.9% for IBx and to 32.6% for RBx overall (p<0.001), while the IBx and RBx rates were 29.0% and 45.5% for G1, 20.0% and 33.3% for G2, 40.0% and 38.9% for G3, and 0% and 0% for G4, respectively (p<0.001). Limitations are the single-institution design, the lack of randomisation, and small samples for subgroup analyses. CONCLUSIONS: mpMRI was of no benefit for men with PSA ≥10ng/ml and +DRE. Among the other men, mpMRI was of benefit in IBx and RBx as would reduce the biopsy rate by up to 25.7% and increase the net HGPC detection rate by up to 28.4%. PATIENT SUMMARY: All men with suspected prostate cancer could benefit from multiparametric prostate cancer and targeted biopsy except for those with prostate-specific antigen ≥10ng/ml and positive digital rectal examination. The benefits include avoiding unnecessary prostate biopsy procedures and increasing the detection of aggressive cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Morote J, Celma A, Roche S, et al. Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer? Eur Urol Oncol. 2018. PMID: 31411977. doi:10.1016/j.euo.2018.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。